Skip to main content
Erschienen in:

11.11.2020 | Epidemiology

Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset

verfasst von: Swati Sakhuja, April Deveaux, Lauren E. Wilson, Neomi Vin-Raviv, Dongyu Zhang, Dejana Braithwaite, Sean Altekruse, Tomi Akinyemiju

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To examine patterns of de-novo metastases (mets) and association with breast cancer-specific mortality across subtypes and racial groups.

Methods

Non-Hispanic (NH) Black and NH-White patients ages 40 years and older with primary breast cancer (BC) between 2010 and 2015 were examined. Multilevel logistic regression and Cox proportional hazards models were used to assess (1) odds of de-novo mets to specific sites by subtype, and (2) association of subtype with risk of BC mortality among patients with de-novo mets by race.

Results

A total of 204,941 BC patients were included in analysis. The most common de-novo mets site was to the bone, and overall prevalence of de-novo mets was higher among NH-Black (6.4%) versus NH-White (4.1%) patients. The odds of de-novo mets to any site were lower for TNBC (OR 0.68, 95% CI 0.62–0.73) and HR+/HER2− (OR 0.50, 95% CI 0.47–0.53) subtypes, but higher for HR−/HER2+ (OR 1.16, 95% CI 1.06–1.28) relative to HR+/HER2+ . De-novo mets to the brain only was associated with the highest mortality risk across all subtypes, ranging from a 13-fold increase (hazard ratio 13.45, 95% CI 5.03–35.96) for HR−/HER2+ to a 39-fold increase (hazard ratio 39.04, 95% CI 26.2–58.14) for HR+/HER2−.

Conclusion

Site and fatality of de-novo mets vary by subtype and by race. This information may help improve risk stratification and post-diagnostic surveillance to ultimately reduce BC mortality.
Literatur
1.
Zurück zum Zitat DeSantis CE, Ma J, Gaudet MM et al (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69(6):438–451CrossRef DeSantis CE, Ma J, Gaudet MM et al (2019) Breast cancer statistics, 2019. CA Cancer J Clin 69(6):438–451CrossRef
2.
Zurück zum Zitat Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21):2492–2502CrossRef Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21):2492–2502CrossRef
3.
Zurück zum Zitat Smith SE, Mellor P, Ward AK et al (2017) Molecular characterization of breast cancer cell lines through multiple omic approaches. Breast Cancer Res 19(1):65CrossRef Smith SE, Mellor P, Ward AK et al (2017) Molecular characterization of breast cancer cell lines through multiple omic approaches. Breast Cancer Res 19(1):65CrossRef
4.
Zurück zum Zitat Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685CrossRef Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685CrossRef
5.
Zurück zum Zitat Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559–1564CrossRef Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331(6024):1559–1564CrossRef
6.
Zurück zum Zitat Soni A, Ren Z, Hameed O et al (2015) Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol 143(4):471–478CrossRef Soni A, Ren Z, Hameed O et al (2015) Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol 143(4):471–478CrossRef
7.
Zurück zum Zitat Malmgren JA, Mayer M, Atwood MK, Kaplan HG (2018) Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat 167(2):579–590CrossRef Malmgren JA, Mayer M, Atwood MK, Kaplan HG (2018) Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat 167(2):579–590CrossRef
8.
Zurück zum Zitat Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M (2017) Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomark Prev 26(6):809–815CrossRef Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M (2017) Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomark Prev 26(6):809–815CrossRef
9.
Zurück zum Zitat Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R (1985) Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56(7):1696–1700CrossRef Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R (1985) Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 56(7):1696–1700CrossRef
10.
Zurück zum Zitat Press DJ, Miller ME, Liederbach E, Yao K, Huo D (2017) De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis 34(8):457–465CrossRef Press DJ, Miller ME, Liederbach E, Yao K, Huo D (2017) De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype. Clin Exp Metastasis 34(8):457–465CrossRef
11.
Zurück zum Zitat Sanpaolo P, Barbieri V, Genovesi D (2011) Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol 37(10):876–882CrossRef Sanpaolo P, Barbieri V, Genovesi D (2011) Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. Eur J Surg Oncol 37(10):876–882CrossRef
12.
Zurück zum Zitat Wu X, Baig A, Kasymjanova G et al (2016) Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus 8(12):e924PubMedPubMedCentral Wu X, Baig A, Kasymjanova G et al (2016) Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus 8(12):e924PubMedPubMedCentral
13.
Zurück zum Zitat Wu SG, Li H, Tang LY et al (2017) The effect of distant metastases sites on survival in de novo stage-IV breast cancer: a SEER database analysis. Tumour Biol 39(6):1010428317705082PubMed Wu SG, Li H, Tang LY et al (2017) The effect of distant metastases sites on survival in de novo stage-IV breast cancer: a SEER database analysis. Tumour Biol 39(6):1010428317705082PubMed
14.
Zurück zum Zitat Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684–1691CrossRef Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28(10):1684–1691CrossRef
15.
Zurück zum Zitat Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA (2017) Factors associated with early mortality among patients with de novo metastatic breast cancer: a population-based study. Oncologist 22(4):386–393CrossRef Vaz-Luis I, Lin NU, Keating NL, Barry WT, Winer EP, Freedman RA (2017) Factors associated with early mortality among patients with de novo metastatic breast cancer: a population-based study. Oncologist 22(4):386–393CrossRef
17.
Zurück zum Zitat Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):3–18 Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):3–18
18.
Zurück zum Zitat Akinyemiju TF, Soliman AS, Johnson NJ et al (2013) Individual and neighborhood socioeconomic status and healthcare resources in relation to black-white breast cancer survival disparities. J Cancer Epidemiol 2013:490472CrossRef Akinyemiju TF, Soliman AS, Johnson NJ et al (2013) Individual and neighborhood socioeconomic status and healthcare resources in relation to black-white breast cancer survival disparities. J Cancer Epidemiol 2013:490472CrossRef
19.
Zurück zum Zitat Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474CrossRef Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17(6):1471–1474CrossRef
20.
Zurück zum Zitat Adamo M, Dickie L, Ruhl J (2018) SEER Program Coding and Staging Manual 2018. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda Adamo M, Dickie L, Ruhl J (2018) SEER Program Coding and Staging Manual 2018. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda
22.
Zurück zum Zitat Gong Y, Liu YR, Ji P, Hu X, Shao ZM (2017) Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep 7:45411CrossRef Gong Y, Liu YR, Ji P, Hu X, Shao ZM (2017) Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep 7:45411CrossRef
23.
Zurück zum Zitat Kaplan MA, Arslan UY, Isikdogan A et al (2016) Biological subtypes and distant relapse pattern in breast cancer patients after curative surgery (study of anatolian society of medical oncology). Breast Care (Basel) 11(4):248–252CrossRef Kaplan MA, Arslan UY, Isikdogan A et al (2016) Biological subtypes and distant relapse pattern in breast cancer patients after curative surgery (study of anatolian society of medical oncology). Breast Care (Basel) 11(4):248–252CrossRef
24.
Zurück zum Zitat Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H (2016) Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 18(1):8CrossRef Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H (2016) Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 18(1):8CrossRef
25.
Zurück zum Zitat Wang R, Zhu Y, Liu X, Liao X, He J, Niu L (2019) The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19(1):1091CrossRef Wang R, Zhu Y, Liu X, Liao X, He J, Niu L (2019) The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19(1):1091CrossRef
26.
Zurück zum Zitat Ording AG, Heide-Jorgensen U, Christiansen CF, Norgaard M, Acquavella J, Sorensen HT (2017) Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study. Clin Exp Metastasis 34(1):93–101CrossRef Ording AG, Heide-Jorgensen U, Christiansen CF, Norgaard M, Acquavella J, Sorensen HT (2017) Site of metastasis and breast cancer mortality: a Danish nationwide registry-based cohort study. Clin Exp Metastasis 34(1):93–101CrossRef
27.
Zurück zum Zitat Scully OJ, Bay BH, Yip G, Yu Y (2012) Breast cancer metastasis. Cancer Genomics Proteomics 9(5):311–320PubMed Scully OJ, Bay BH, Yip G, Yu Y (2012) Breast cancer metastasis. Cancer Genomics Proteomics 9(5):311–320PubMed
28.
Zurück zum Zitat Cole SW (2009) Chronic inflammation and breast cancer recurrence. J Clin Oncol 27(21):3418–3419CrossRef Cole SW (2009) Chronic inflammation and breast cancer recurrence. J Clin Oncol 27(21):3418–3419CrossRef
29.
Zurück zum Zitat Marvel D, Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Investig 125(9):3356–3364CrossRef Marvel D, Gabrilovich DI (2015) Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Investig 125(9):3356–3364CrossRef
30.
Zurück zum Zitat Huber MA, Azoitei N, Baumann B et al (2004) NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Investig 114(4):569–581CrossRef Huber MA, Azoitei N, Baumann B et al (2004) NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Investig 114(4):569–581CrossRef
31.
Zurück zum Zitat Takai K, Le A, Weaver VM, Werb Z (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7(50):82889–82901CrossRef Takai K, Le A, Weaver VM, Werb Z (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7(50):82889–82901CrossRef
32.
Zurück zum Zitat Sa-nguanraksa D, O-charoenrat P (2012) The role of vascular endothelial growth factor A polymorphisms in breast cancer. Int J Mol Sci 13(11):14845–14864CrossRef Sa-nguanraksa D, O-charoenrat P (2012) The role of vascular endothelial growth factor A polymorphisms in breast cancer. Int J Mol Sci 13(11):14845–14864CrossRef
33.
Zurück zum Zitat Foroni C, Broggini M, Generali D, Damia G (2012) Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev 38(6):689–697CrossRef Foroni C, Broggini M, Generali D, Damia G (2012) Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev 38(6):689–697CrossRef
34.
Zurück zum Zitat Subramani R, Nandy SB, Pedroza DA, Lakshmanaswamy R (2017) Role of growth hormone in breast cancer. Endocrinology 158(6):1543–1555CrossRef Subramani R, Nandy SB, Pedroza DA, Lakshmanaswamy R (2017) Role of growth hormone in breast cancer. Endocrinology 158(6):1543–1555CrossRef
Metadaten
Titel
Patterns of de-novo metastasis and breast cancer-specific mortality by race and molecular subtype in the SEER population-based dataset
verfasst von
Swati Sakhuja
April Deveaux
Lauren E. Wilson
Neomi Vin-Raviv
Dongyu Zhang
Dejana Braithwaite
Sean Altekruse
Tomi Akinyemiju
Publikationsdatum
11.11.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-06007-4

Neu im Fachgebiet Onkologie

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Brustkrebstherapie: zu wenig Aufklärung über Nebenwirkungen?

Ergebnisse eines internationalen Surveys legen nahe, dass die Aufklärung über Nebenwirkungen einer Brustkrebstherapie häufig unzureichend ausfällt bzw. zu spät erfolgt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.